Vir Biotechnology (NASDAQ:VIR – Get Rating) was upgraded by stock analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating in a research report issued to clients and investors on Friday, Marketbeat.com reports. The brokerage currently has a $30.00 price target on the stock, up from their previous price target of $18.00. Morgan Stanley's price target would suggest a potential downside of 2.76% from the company's current price.

A number of other equities research analysts have also recently issued reports on the company. Needham & Company LLC dropped their price objective on Vir Biotechnology from $35.00 to $32.00 and set a "buy" rating on the stock in a research note on Friday, November 4th. TheStreet upgraded Vir Biotechnology from a "d" rating to a "c-" rating in a research note on Monday, October 10th. Finally, SVB Leerink upped their price objective on Vir Biotechnology from $40.00 to $45.00 and gave the stock an "outperform" rating in a research note on Friday, November 4th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Vir Biotechnology currently has a consensus rating of "Moderate Buy" and a consensus target price of $54.17.

Vir Biotechnology Stock Up 2.9 %

NASDAQ:VIR opened at $30.85 on Friday. Vir Biotechnology has a twelve month low of $18.05 and a twelve month high of $35.48. The business has a 50 day moving average price of $26.59 and a two-hundred day moving average price of $25.11. The company has a market cap of $4.11 billion, a P/E ratio of 3.63 and a beta of 0.15.

Insider Activity at Vir Biotechnology

In related news, Director Vicki L. Sato sold 17,915 shares of the stock in a transaction on Tuesday, November 8th. The stock was sold at an average price of $27.38, for a total value of $490,512.70. Following the sale, the director now owns 1,399,004 shares in the company, valued at approximately $38,304,729.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf sold 50,173 shares of the stock in a transaction on Monday, November 14th. The stock was sold at an average price of $27.41, for a total transaction of $1,375,241.93. Following the transaction, the insider now owns 21,566,288 shares in the company, valued at approximately $591,131,954.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Vicki L. Sato sold 17,915 shares of the stock in a transaction on Tuesday, November 8th. The stock was sold at an average price of $27.38, for a total value of $490,512.70. Following the transaction, the director now owns 1,399,004 shares in the company, valued at approximately $38,304,729.52. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,316,352 shares of company stock worth $35,377,784. Company insiders own 22.40% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. acquired a new stake in shares of Vir Biotechnology during the 3rd quarter worth $635,000. Shell Asset Management Co. grew its holdings in shares of Vir Biotechnology by 283.7% during the 2nd quarter. Shell Asset Management Co. now owns 11,253 shares of the company's stock worth $287,000 after purchasing an additional 8,320 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Vir Biotechnology during the 2nd quarter worth $8,207,000. SummerHaven Investment Management LLC acquired a new stake in shares of Vir Biotechnology during the 3rd quarter worth $481,000. Finally, Everence Capital Management Inc. acquired a new stake in shares of Vir Biotechnology during the 2nd quarter worth $259,000. Institutional investors own 74.97% of the company's stock.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Featured Articles

• Get a free copy of the StockNews.com research report on Vir Biotechnology (VIR)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.